Rhythm Pharmaceuticals (RYTM) News Today $63.66 +1.53 (+2.46%) Closing price 06/24/2025 04:00 PM EasternExtended Trading$64.08 +0.42 (+0.65%) As of 06/24/2025 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RYTM Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Avior Wealth Management LLC Invests $243,000 in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Avior Wealth Management LLC bought a new position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 4,589 shares of the company's stock, valueJune 24 at 3:52 AM | marketbeat.com22,192 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Bought by Assenagon Asset Management S.A.Assenagon Asset Management S.A. purchased a new position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 22,192 shares of the company'sJune 18, 2025 | marketbeat.comSG Americas Securities LLC Buys Shares of 19,667 Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)SG Americas Securities LLC purchased a new position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 19,667 shares of the company's stock, valued at approximaJune 18, 2025 | marketbeat.comGAMMA Investing LLC Grows Stock Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)GAMMA Investing LLC boosted its stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 7,305.5% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 14,885 shares of the company's stock after purchasing an additional 14,684 shares during the period. GAMJune 18, 2025 | marketbeat.comInsider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Sells 2,069 Shares of StockRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) CAO Christopher Paul German sold 2,069 shares of Rhythm Pharmaceuticals stock in a transaction that occurred on Tuesday, June 10th. The stock was sold at an average price of $67.19, for a total value of $139,016.11. Following the completion of the transaction, the chief accounting officer now owns 1,889 shares of the company's stock, valued at approximately $126,921.91. This trade represents a 52.27% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.June 12, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Consensus Recommendation of "Buy" from AnalystsRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) has received a consensus recommendation of "Buy" from the thirteen analysts that are presently covering the firm, MarketBeat.com reports. Thirteen investment analysts have rated the stock with a buy rating. The average 12 month price objJune 12, 2025 | marketbeat.comHarbor Capital Advisors Inc. Buys 47,045 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Harbor Capital Advisors Inc. grew its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 155.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 77,297 shares of the company's stock after bJune 11, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Sold by Wedge Capital Management L L P NCWedge Capital Management L L P NC trimmed its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 23.6% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 36,984 shares of the company's stock afterJune 11, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells $478,459.55 in StockRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) insider Pamela J. Cramer sold 7,031 shares of the company's stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $68.05, for a total value of $478,459.55. Following the completion of the sale, the insider now owns 19,209 shares of the company's stock, valued at $1,307,172.45. This represents a 26.79% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.June 10, 2025 | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Reaches New 1-Year High - Should You Buy?Rhythm Pharmaceuticals (NASDAQ:RYTM) Sets New 1-Year High - Here's WhyJune 9, 2025 | marketbeat.comThe Rhythm Foundation seeks contract extension to continue programming at Miami Beach BandshellJune 7, 2025 | msn.comMillennium Management LLC Sells 21,718 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Millennium Management LLC lowered its stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 58.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,259 shares of the compaJune 7, 2025 | marketbeat.comJefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price TargetJune 5, 2025 | msn.comHere's How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 YearsJune 5, 2025 | benzinga.comHennion & Walsh Asset Management Inc. Has $4.75 Million Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Hennion & Walsh Asset Management Inc. cut its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 9.9% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 89,622 shares of the company's stock after selling 9,825June 4, 2025 | marketbeat.com76,084 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Bought by Universal Beteiligungs und Servicegesellschaft mbHUniversal Beteiligungs und Servicegesellschaft mbH acquired a new position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 76,084 shares of the comJune 2, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Holdings Cut by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 3.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional invMay 31, 2025 | marketbeat.comStifel Nicolaus Raises Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $94.00Stifel Nicolaus boosted their price objective on Rhythm Pharmaceuticals from $78.00 to $94.00 and gave the company a "buy" rating in a research note on Thursday.May 30, 2025 | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Trading Up 4.7% - Here's WhyRhythm Pharmaceuticals (NASDAQ:RYTM) Shares Up 4.7% - Time to Buy?May 30, 2025 | marketbeat.comRhythm Pharmaceuticals (RYTM) Gets Price Target Upgrade by Stifel Amid Obesity Drug OptimismMay 30, 2025 | msn.com3RYTM : 12 Analysts Assess Rhythm Pharmaceuticals: What You Need To KnowMay 29, 2025 | benzinga.comRhythm Pharmaceuticals (NASDAQ:RYTM) Trading Down 4.1% - Should You Sell?Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Down 4.1% - Should You Sell?May 29, 2025 | marketbeat.comFunds Go All In On Weight-Loss Leader; Stock Nears HighsMay 29, 2025 | investors.comAmeriprise Financial Inc. Purchases 11,480 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Ameriprise Financial Inc. raised its stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 27.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 53,367 shares of the company's stock afterMay 29, 2025 | marketbeat.comVoloridge Investment Management LLC Purchases 27,214 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Voloridge Investment Management LLC boosted its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 7.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 380,537 shares of the company's stock afMay 25, 2025 | marketbeat.comProShare Advisors LLC Grows Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)ProShare Advisors LLC increased its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 31.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 18,328 shares ofMay 25, 2025 | marketbeat.comDeutsche Bank AG Has $2.73 Million Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Deutsche Bank AG increased its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 46.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 48,745 shares of the company's stock after purchasing an additional 15,481 sharMay 24, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Position Trimmed by Frazier Life Sciences Management L.P.Frazier Life Sciences Management L.P. lessened its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 22.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,869,808 shares of the compMay 23, 2025 | marketbeat.comRafferty Asset Management LLC Sells 14,182 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Rafferty Asset Management LLC cut its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 22.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 50,394 shares of the company'May 22, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Buys 43,904 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)D. E. Shaw & Co. Inc. increased its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 1,022.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 48,198 shares of the company's stock after purchasing an additional 43,May 22, 2025 | marketbeat.comOMERS ADMINISTRATION Corp Takes $425,000 Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)OMERS ADMINISTRATION Corp purchased a new position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 7,600 shares of the company's stock, valued at approximately $425,000. Other insMay 21, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Average Rating of "Buy" from AnalystsRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) has earned a consensus rating of "Buy" from the thirteen brokerages that are presently covering the firm, MarketBeat Ratings reports. Thirteen research analysts have rated the stock with a buy recommendation. The average 1-year target prMay 20, 2025 | marketbeat.comLazard Asset Management LLC Acquires New Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Lazard Asset Management LLC acquired a new stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 106,261 shares of the company's stock, valued at approximateMay 18, 2025 | marketbeat.comJanus Henderson Group PLC Acquires 621,432 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Janus Henderson Group PLC boosted its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 103.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,219,554 shares of the compMay 16, 2025 | marketbeat.comBNP Paribas Financial Markets Purchases 70,824 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)BNP Paribas Financial Markets raised its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 491.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 85,249 shares of the compMay 16, 2025 | marketbeat.comOrbimed Advisors LLC Reduces Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Orbimed Advisors LLC decreased its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 8.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 400,000 shares of the company's stocMay 15, 2025 | marketbeat.comRhythm FY Net Y758.00M Vs Net Y477.00MMay 14, 2025 | marketwatch.comRhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access ProgramMay 14, 2025 | globenewswire.comIntegral Health Asset Management LLC Invests $8.40 Million in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Integral Health Asset Management LLC purchased a new position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 150,000 shares of the company's stock, valuMay 14, 2025 | marketbeat.comNorthern Trust Corp Has $30.53 Million Stock Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Northern Trust Corp grew its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 9.4% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 545,314 shares of the company's stock after purchasing an additiMay 13, 2025 | marketbeat.comHC Wainwright Has Negative Estimate for RYTM Q2 EarningsRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) - Research analysts at HC Wainwright decreased their Q2 2025 earnings estimates for Rhythm Pharmaceuticals in a research note issued on Thursday, May 8th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($0.76) pMay 13, 2025 | marketbeat.com138,363 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Acquired by Balyasny Asset Management L.P.Balyasny Asset Management L.P. acquired a new stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 138,363 shares of the company's stock, valMay 12, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Purchased by The Manufacturers Life Insurance CompanyThe Manufacturers Life Insurance Company increased its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 23.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 59,969 shares of the company's stock after purcMay 12, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Acquired by Crestline Management LPCrestline Management LP lifted its stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 31.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 25,062 shares of the company's stock after purchasing an additional 6,0May 11, 2025 | marketbeat.comAlgert Global LLC Reduces Stock Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Algert Global LLC lessened its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 23.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 41,551 shares of the company's stockMay 11, 2025 | marketbeat.comDriehaus Capital Management LLC Sells 8,515 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Driehaus Capital Management LLC cut its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 0.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,290,975May 10, 2025 | marketbeat.comBridgefront Capital LLC Makes New Investment in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Bridgefront Capital LLC acquired a new stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 4,604 shares of the company's stock, valued at approximately $258,000. A number ofMay 10, 2025 | marketbeat.comEarnings call transcript: Rhythm Pharmaceuticals misses Q1 2025 EPS estimatesMay 9, 2025 | uk.investing.comRhythm Pharmaceuticals, Inc. (RYTM) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comTudor Investment Corp ET AL Invests $853,000 in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Tudor Investment Corp ET AL bought a new position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 15,245 shares of the company's stock, valued at approximatMay 9, 2025 | marketbeat.com Get Rhythm Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter. Email Address RYTM Media Mentions By Week RYTM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RYTM News Sentiment▼1.830.62▲Average Medical News Sentiment RYTM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RYTM Articles This Week▼48▲RYTM Articles Average Week Get Rhythm Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Summit Therapeutics News Today Genmab A/S News Today Intra-Cellular Therapies News Today Dr. Reddy's Laboratories News Today Ascendis Pharma A/S News Today Viatris News Today Qiagen News Today Moderna News Today Blueprint Medicines News Today BridgeBio Pharma News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RYTM) was last updated on 6/25/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rhythm Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
